Physician profile
Sarah Bier
NPI 1962920884
$6,849.58
in general payments reported to CMS, 2019-2025
21 companies · $2,350 in 2025
The $2,350 reported for 2025 was more than what 99% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $319 · 2023: $1,309 · 2024: $2,871 · 2025: $2,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,307 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,307.36 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $956.96 | 2022-2025 | Caplyta |
| Abbvie INC. | $943.28 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $835.99 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $725.15 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $677.15 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $630.85 | 2022-2025 | Auvelity |
| Alkermes, INC. | $536.18 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $394.00 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $245.06 | 2022-2024 | Rexulti, Abilify Asimtufii, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $235.92 | 2025 | Cobenfy |
| Bausch Health US, LLC | $134.86 | 2022-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $109.25 | 2023-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $91.61 | 2023-2024 | Quviviq |
| Indivior INC. | $66.27 | 2023-2024 | Perseris, Sublocade |
| Janssen Pharmaceuticals, INC | $65.72 | 2024-2025 | Invega Sustenna, Spravato |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $53.42 | 2025 | Xelstrym, Secuado |
| Uswm, LLC | $52.80 | 2022-2023 | Zimhi, Lucemyra |
| Supernus Pharmaceuticals, INC. | $38.55 | 2023 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.40 | 2023 | Rexulti |
| Neos Therapeutics, Lp | $20.67 | 2024 | Adzenys Xr-Odt |
| Organon LLC | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.